)
Coherus Oncology (CHRS) investor relations material
Coherus Oncology Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic focus and operating model
Development focus narrowed to tagmokitug and esophageal cancer after completing studies across six indications; estimated global esophageal cancer population is 400,000–500,000.
Headcount reduced from about 140 to about 100; quarterly burn lowered by $6 million–$7 million, with the sales hurdle for core cash burn reduced to $25 million–$30 million per quarter.
Pasritamig prostate study with J&J was expected to dose its first patient that week or the following week; rationale is that Treg depletion may remodel the tumor microenvironment for T-cell engagement.
Tagmokitug clinical results
First-line esophageal data updated from 6/8 responders (75%) to 8/9 (89%) after the Oct. 14 data cut; ORR was 100% among PD-L1-positive patients.
Interim ctDNA declines tracked with partial or complete responses among patients with available samples; one patient may have had complete ctDNA disappearance.
Second-line esophageal results included 33% confirmed and 44% unconfirmed ORR versus about 10% for chemotherapy; median PFS was 5.5 months versus 2.5–3.5 months for standard-of-care chemotherapy.
First-line discontinuations attributed to treatment-related adverse events from tagmokitug included cases the speaker said were due to chemotherapy; follow-on studies plan to change the chemotherapy regimen.
Development plans and partnering
Planned first step is an FDA discussion on second-line esophageal development and a potential accelerated-approval strategy; a randomized study would enroll patients progressing after first-line PD-1 plus chemotherapy.
Proposed second-line study would compare the triplet with physician-choice chemotherapy; ORR is the primary endpoint, with PFS and OS as secondary endpoints, and 1:1 or 2:1 randomization under discussion.
The regulatory package was being prepared for filing by year-end; the proposed trial is multi-regional, with partnership discussions underway in Asia, including Japan, Korea and China.
First-line plan is tagmokitug plus PD-1 and chemotherapy versus PD-1 plus chemotherapy, with potential activity irrespective of PD-L1 status.
- Tagmokitug’s esophageal cancer signals lead a focused pipeline backed by LOQTORZI revenue.CHRS
Corporate presentation - Promising esophageal data drive a focused development plan and cost reset.CHRS
3rd Annual Guggenheim Healthcare Innovation Conference - LOQTORZI growth and cost cuts sharpen esophageal focus amid persistent liquidity doubts.CHRS
Q3 2026 - 2026 readouts across two immunotherapy programs; LOQTORZI targets core-cost coverage in 2027.CHRS
2026 Global Healthcare Conference - TREGCHECK showed interim ESCC activity, including 89% 1L cORR after later confirmations.CHRS
Study result - Strong commercial growth and promising oncology pipeline drive optimism for future milestones.CHRS
Morgan Stanley 24th Annual Global Healthcare Conference - Innovative oncology focus drives pipeline progress, with key data readouts expected by year-end.CHRS
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 revenue rose up to 40% year-over-year, but ongoing losses and funding needs persist.CHRS
Q2 2026 - Advancing innovative oncology assets with strong early data and robust financial backing.CHRS
The Citizens JMP Life Sciences Conference 2025
)
)
)
)
)
)
)
)